scholarly journals A comprehensive approach to stool donor screening for faecal microbiota transplantation in China

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Jianquan He ◽  
Xingxiang He ◽  
Yonghui Ma ◽  
Luxi Yang ◽  
Haiming Fang ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Online Survey ◽  
Ethical Issues ◽  
Selection Process ◽  
Faecal Microbiota ◽  
Bioinformatics Analyses ◽  
Screening Process ◽  
Faecal Microbiota Transplantation ◽  
Donor Screening ◽  
Reference Index

Abstract Background Faecal microbiota transplantation (FMT) is an effective therapy for recurrent Clostridium difficile infections and chronic gastrointestional infections. However, the risks of FMT and the selection process of suitable donors remain insufficiently characterized. The eligibility rate for screening, underlying microbial basis, and core ethical issues of stool donors for FMT are yet to be elucidated in China. Results The potential stool donors were screened from December 2017 to December 2019 with the help of an online survey, clinical assessments, and stool and blood testing. Bioinformatics analyses were performed, and the composition and stability of gut microbiota in stool obtained from eligible donors were dynamically observed using metagenomics. Meanwhile, we build a donor microbial evaluation index (DoMEI) for stool donor screening. In the screening process, we also focused on ethical principles and requirements. Of the 2071 participants, 66 donors were selected via the screening process (3.19% success rate). Although there were significant differences in gut microbiota among donors, we found that the changes in the gut microbiota of the same donor were typically more stable than those between donors over time. Conclusions DoMEI provides a potential reference index for regular stool donor re-evaluation. In this retrospective study, we summarised the donor recruitment and screening procedure ensuring the safety and tolerability for FMT in China. Based on the latest advances in this field, we carried out rigorous recommendation and method which can assist stool bank and clinicians to screen eligible stool donor for FMT.

scholarly journals The Rigorous Screening and Ethics of Donor for Faecal Microbiota Transplantation in China

2021 ◽  
Author(s):  
Jianquan He ◽  
Xingxiang He ◽  
Yonghui Ma ◽  
Luxi Yang ◽  
Haiming Fang ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Online Survey ◽  
Ethical Issues ◽  
Selection Process ◽  
Faecal Microbiota ◽  
Bioinformatics Analyses ◽  
Screening Process ◽  
Faecal Microbiota Transplantation ◽  
Donor Screening ◽  
Reference Index

Abstract Background: Faecal microbiota transplantation (FMT) is a safe and effective therapy for recurrent Clostridium difficile infections and some gastrointestinal and systemic diseases. However, the risks of FMT and the selection process of suitable donors remain insufficiently characterized. The eligibility rate for screening, underlying microbial basis, and core ethical issues of stool donors for FMT are yet to be elucidated in China. Results：The potential stool donors were screened from December 2017 to December 2019 with the help of an online survey, clinical assessments, and stool and blood testing. Bioinformatics analyses were performed, and the composition and stability of gut microbiota in stool obtained from eligible donors were dynamically observed using metagenomics. Meanwhile, we build a donor microbial evaluation index (DoMEI) for stool donor screening. In the screening process, we also focused on ethical principles and requirements. Of the 2071 participants, 66 donors were selected via the screening process (3.19% success rate). Although there were significant differences in gut microbiota among donors, we found that the changes in the gut microbiota of the same donor were typically more stable than those between donors over time. Conclusions: The DoMEI provides a potential reference index for stool donor re-evaluation. In this retrospective study, we summarised the donor recruitment and screening procedure for FMT in China. Based on the latest advances in this field, we carried out a rigorous faecal microbiota donor screening process.

scholarly journals Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study

Gut ◽  
2018 ◽  
Vol 67 (12) ◽  
pp. 2107-2115 ◽  
Author(s):  
Sofie Ingdam Halkjær ◽  
Alice Højer Christensen ◽  
Bobby Zhao Sheng Lo ◽  
Patrick Denis Browne ◽  
Stig Günther ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Controlled Trial ◽  
Symptom Relief ◽  
Controlled Study ◽  
Faecal Microbiota ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Faecal Microbiota Transplantation ◽  
Faecal Samples ◽  
Significant Difference

ObjectiveIBS is associated with an intestinal dysbiosis and faecal microbiota transplantation (FMT) has been hypothesised to have a positive effect in patients with IBS. We performed a randomised, double-blind placebo-controlled trial to investigate if FMT resulted in an altered gut microbiota and improvement in clinical outcome in patients with IBS.DesignWe performed this study in 52 adult patients with moderate-to-severe IBS. At the screening visit, clinical history and symptoms were assessed and faecal samples were collected. Patients were randomised to FMT or placebo capsules for 12 days and followed for 6 months. Study visits were performed at baseline, 1, 3 and 6 months, where patients were asked to register their symptoms using the IBS-severity scoring system (IBS-SSS) and IBS-specific quality of life (IBS-QoL). Prior to each visit, faecal samples were collected.ResultsA significant difference in improvement in IBS-SSS score was observed 3 months after treatment (p=0.012) favouring placebo. This was similar for IBS-QoL data after 3 months (p=0.003) favouring placebo. Patients receiving FMT capsules had an increase in faecal microbial biodiversity while placebos did not.ConclusionIn this randomised double-blinded placebo-controlled study, we found that FMT changed gut microbiota in patients with IBS. But patients in the placebo group experienced greater symptom relief compared with the FMT group after 3 months. Altering the gut microbiota is not enough to obtain clinical improvement in IBS. However, different study designs and larger studies are required to examine the role of FMT in IBS.Trial registration numberNCT02788071.

scholarly journals International consensus conference on stool banking for faecal microbiota transplantation in clinical practice

Gut ◽  
2019 ◽  
Vol 68 (12) ◽  
pp. 2111-2121 ◽  
Author(s):  
Giovanni Cammarota ◽  
Gianluca Ianiro ◽  
Colleen R Kelly ◽  
Benjamin H Mullish ◽  
Jessica R Allegretti ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Ethical Issues ◽  
Consensus Conference ◽  
Faecal Microbiota ◽  
International Consensus ◽  
Face To Face ◽  
Faecal Microbiota Transplantation ◽  
Clostridioides Difficile

Although faecal microbiota transplantation (FMT) has a well-established role in the treatment of recurrent Clostridioides difficile infection (CDI), its widespread dissemination is limited by several obstacles, including lack of dedicated centres, difficulties with donor recruitment and complexities related to regulation and safety monitoring. Given the considerable burden of CDI on global healthcare systems, FMT should be widely available to most centres.Stool banks may guarantee reliable, timely and equitable access to FMT for patients and a traceable workflow that ensures safety and quality of procedures. In this consensus project, FMT experts from Europe, North America and Australia gathered and released statements on the following issues related to the stool banking: general principles, objectives and organisation of the stool bank; selection and screening of donors; collection, preparation and storage of faeces; services and clients; registries, monitoring of outcomes and ethical issues; and the evolving role of FMT in clinical practice,Consensus on each statement was achieved through a Delphi process and then in a plenary face-to-face meeting. For each key issue, the best available evidence was assessed, with the aim of providing guidance for the development of stool banks in order to promote accessibility to FMT in clinical practice.

scholarly journals Capsulized faecal microbiota transplantation ameliorates post-weaning diarrhoea by modulating the gut microbiota in piglets

2020 ◽  
Vol 51 (1) ◽  
Author(s):  
Wenjie Tang ◽  
Daiwen Chen ◽  
Bing Yu ◽  
Jun He ◽  
Zhiqing Huang ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Faecal Microbiota ◽  
Faecal Microbiota Transplantation

scholarly journals Gut Microbiota and Parkinson’s Disease: Implications for Faecal Microbiota Transplantation Therapy

ASN NEURO ◽  
2021 ◽  
Vol 13 ◽  
pp. 175909142110162
Author(s):  
Yongbo Kang ◽  
Xing Kang ◽  
Hongfang Zhang ◽  
Qingqing Liu ◽  
Hao Yang ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Nervous System ◽  
Gut Microbiota ◽  
Faecal Microbiota ◽  
Faecal Microbiota Transplantation ◽  
Microbial Dysbiosis ◽  
The Future ◽  
The Central Nervous System ◽  
Microbial Strains

Parkinson's disease (PD) ranks the second place among neurodegenerative diseases in terms of its morbidity, which affects 1-2% people aged over 65 years. In addition to genetics, some environmental factors may exert vital parts in PD occurrence as well. At present, more and more studies are conducted to elucidate the association between gut microbial dysbiosis and the incidence of PD. Gut microbial dysbiosis has a certain effect on both the central nervous system (CNS) and the enteric nervous system (ENS), which indicates that there is a gut-microbiota-brain axis that induces CNS disorders. Some gut microbial strains are suggested to suppress or weaken the neuroinflammation- and gut-inflammation-immune responses, which suggests the protective and pathogenic effects of certain gut microbial species on PD progression. Therefore, gut microbiome may contain plenty of targets for preventing and managing PD. Faecal microbiota transplantation (FMT) may serve as a direct and useful treatment for PD in the future. Nonetheless, there is little available scientific research in this field. The present work reviewed the latest research to examine the association of gut microbiota with PD, and the future prospects of FMT treatment.

Sign in / Sign up

Export Citation Format

Share Document